Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoadjuvant Therapy | 15 | 2023 | 2895 | 1.680 |
Why?
|
Rectal Neoplasms | 9 | 2024 | 1182 | 1.610 |
Why?
|
Esophageal Neoplasms | 10 | 2024 | 1661 | 1.470 |
Why?
|
Esophagectomy | 8 | 2020 | 477 | 1.410 |
Why?
|
Adenocarcinoma | 17 | 2024 | 6364 | 1.310 |
Why?
|
Pancreatic Neoplasms | 12 | 2023 | 5444 | 1.300 |
Why?
|
Anus Neoplasms | 4 | 2022 | 336 | 1.020 |
Why?
|
Deoxycytidine | 4 | 2018 | 889 | 0.820 |
Why?
|
Hematologic Diseases | 2 | 2018 | 500 | 0.820 |
Why?
|
Carcinoma, Squamous Cell | 6 | 2017 | 4044 | 0.770 |
Why?
|
Biliary Tract Surgical Procedures | 1 | 2020 | 50 | 0.690 |
Why?
|
Radiation Oncology | 2 | 2016 | 569 | 0.650 |
Why?
|
Pelvic Neoplasms | 1 | 2020 | 247 | 0.610 |
Why?
|
Biliary Tract Neoplasms | 1 | 2020 | 186 | 0.610 |
Why?
|
Radiosurgery | 5 | 2020 | 1328 | 0.570 |
Why?
|
Radiation Injuries, Experimental | 1 | 2017 | 88 | 0.550 |
Why?
|
Radiotherapy, Intensity-Modulated | 3 | 2022 | 784 | 0.540 |
Why?
|
Splenomegaly | 1 | 2016 | 192 | 0.520 |
Why?
|
Radiotherapy Dosage | 7 | 2021 | 2865 | 0.510 |
Why?
|
GTP Phosphohydrolases | 1 | 2019 | 523 | 0.510 |
Why?
|
Neoplasm Staging | 14 | 2024 | 11206 | 0.490 |
Why?
|
Radiation Pneumonitis | 1 | 2016 | 98 | 0.490 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2022 | 1761 | 0.480 |
Why?
|
Taxoids | 1 | 2016 | 665 | 0.400 |
Why?
|
Radiation Injuries | 2 | 2018 | 1181 | 0.380 |
Why?
|
Radiometry | 2 | 2016 | 804 | 0.360 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2021 | 9373 | 0.360 |
Why?
|
Neoplasm, Residual | 1 | 2015 | 1009 | 0.350 |
Why?
|
Morbidity | 1 | 2015 | 1749 | 0.340 |
Why?
|
Program Development | 1 | 2016 | 1295 | 0.330 |
Why?
|
Guidelines as Topic | 1 | 2016 | 1394 | 0.320 |
Why?
|
Transforming Growth Factor beta | 1 | 2017 | 1995 | 0.320 |
Why?
|
Aged, 80 and over | 20 | 2021 | 59489 | 0.300 |
Why?
|
Aged | 35 | 2024 | 171117 | 0.300 |
Why?
|
HIV Seropositivity | 1 | 2013 | 961 | 0.300 |
Why?
|
Radiotherapy | 4 | 2017 | 1494 | 0.290 |
Why?
|
High-Intensity Focused Ultrasound Ablation | 2 | 2021 | 42 | 0.290 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 8 | 2024 | 11868 | 0.280 |
Why?
|
Colonic Neoplasms | 1 | 2019 | 2531 | 0.280 |
Why?
|
Neoplasms | 7 | 2023 | 22340 | 0.250 |
Why?
|
Middle Aged | 34 | 2024 | 223009 | 0.250 |
Why?
|
Combined Modality Therapy | 5 | 2017 | 8529 | 0.240 |
Why?
|
Hematologic Neoplasms | 1 | 2016 | 1927 | 0.240 |
Why?
|
Lymph Nodes | 1 | 2016 | 3454 | 0.230 |
Why?
|
Brachytherapy | 2 | 2022 | 1222 | 0.230 |
Why?
|
Genetic Variation | 1 | 2019 | 6610 | 0.220 |
Why?
|
Neoplasm Invasiveness | 3 | 2018 | 3602 | 0.210 |
Why?
|
Nutritional Status | 2 | 2023 | 1620 | 0.210 |
Why?
|
Humans | 59 | 2024 | 765968 | 0.210 |
Why?
|
Membrane Proteins | 1 | 2019 | 7851 | 0.200 |
Why?
|
SEER Program | 3 | 2016 | 1446 | 0.200 |
Why?
|
Prognosis | 9 | 2021 | 29922 | 0.200 |
Why?
|
Students, Medical | 1 | 2015 | 1959 | 0.200 |
Why?
|
Male | 33 | 2024 | 363698 | 0.190 |
Why?
|
Length of Stay | 1 | 2015 | 6485 | 0.190 |
Why?
|
Papillomavirus Infections | 1 | 2013 | 1640 | 0.190 |
Why?
|
Bone Neoplasms | 3 | 2021 | 2567 | 0.190 |
Why?
|
Neoplasm Proteins | 1 | 2013 | 3596 | 0.190 |
Why?
|
Adult | 25 | 2024 | 223044 | 0.180 |
Why?
|
Retrospective Studies | 18 | 2024 | 81514 | 0.180 |
Why?
|
Female | 34 | 2024 | 396112 | 0.180 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 4058 | 0.180 |
Why?
|
Jejunostomy | 1 | 2020 | 61 | 0.170 |
Why?
|
Lung Neoplasms | 5 | 2022 | 13451 | 0.170 |
Why?
|
Radiotherapy, Conformal | 1 | 2022 | 533 | 0.160 |
Why?
|
Antineoplastic Agents | 3 | 2022 | 13648 | 0.160 |
Why?
|
Microsatellite Instability | 2 | 2022 | 728 | 0.160 |
Why?
|
Paclitaxel | 2 | 2024 | 1728 | 0.160 |
Why?
|
Primary Health Care | 1 | 2015 | 4736 | 0.160 |
Why?
|
Internship and Residency | 2 | 2016 | 5946 | 0.160 |
Why?
|
Survival Rate | 7 | 2024 | 12795 | 0.150 |
Why?
|
Cisplatin | 1 | 2024 | 1658 | 0.150 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2021 | 335 | 0.150 |
Why?
|
Radiodermatitis | 1 | 2017 | 58 | 0.140 |
Why?
|
Logistic Models | 3 | 2017 | 13266 | 0.140 |
Why?
|
Behavior Therapy | 1 | 2023 | 884 | 0.140 |
Why?
|
ras Proteins | 1 | 2022 | 1053 | 0.140 |
Why?
|
Fractures, Spontaneous | 1 | 2018 | 230 | 0.140 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2017 | 869 | 0.140 |
Why?
|
Colorectal Neoplasms | 3 | 2022 | 6942 | 0.130 |
Why?
|
Peritoneal Neoplasms | 2 | 2021 | 703 | 0.130 |
Why?
|
PTEN Phosphohydrolase | 1 | 2022 | 1119 | 0.130 |
Why?
|
Therapeutic Misconception | 1 | 2015 | 10 | 0.130 |
Why?
|
DNA Mutational Analysis | 3 | 2022 | 4108 | 0.130 |
Why?
|
Disease-Free Survival | 4 | 2023 | 6832 | 0.120 |
Why?
|
Job Description | 1 | 2015 | 61 | 0.120 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2018 | 248 | 0.120 |
Why?
|
Rectum | 1 | 2020 | 896 | 0.120 |
Why?
|
Cancer Care Facilities | 1 | 2018 | 426 | 0.120 |
Why?
|
DNA Mismatch Repair | 1 | 2018 | 433 | 0.120 |
Why?
|
Survival Analysis | 5 | 2020 | 10070 | 0.120 |
Why?
|
Liver Neoplasms | 3 | 2022 | 4353 | 0.120 |
Why?
|
Poisson Distribution | 1 | 2016 | 508 | 0.110 |
Why?
|
Enteral Nutrition | 1 | 2020 | 803 | 0.110 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2016 | 307 | 0.110 |
Why?
|
Postoperative Complications | 2 | 2021 | 15747 | 0.110 |
Why?
|
Structure-Activity Relationship | 1 | 2019 | 3051 | 0.110 |
Why?
|
Chi-Square Distribution | 2 | 2017 | 3432 | 0.110 |
Why?
|
Kaplan-Meier Estimate | 3 | 2024 | 6499 | 0.110 |
Why?
|
Pancreatectomy | 2 | 2021 | 820 | 0.110 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 5389 | 0.100 |
Why?
|
Embolization, Therapeutic | 1 | 2022 | 1403 | 0.100 |
Why?
|
Organ Specificity | 1 | 2017 | 1965 | 0.100 |
Why?
|
Health Status Disparities | 1 | 2024 | 1880 | 0.100 |
Why?
|
Time Factors | 5 | 2017 | 40065 | 0.100 |
Why?
|
Regression Analysis | 2 | 2018 | 6322 | 0.090 |
Why?
|
United States | 9 | 2024 | 72903 | 0.090 |
Why?
|
Adipose Tissue | 1 | 2023 | 3312 | 0.090 |
Why?
|
Intestine, Small | 1 | 2017 | 1214 | 0.090 |
Why?
|
Treatment Outcome | 10 | 2024 | 65188 | 0.090 |
Why?
|
Spleen | 1 | 2016 | 2296 | 0.090 |
Why?
|
Immunoenzyme Techniques | 1 | 2013 | 1701 | 0.090 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2013 | 703 | 0.090 |
Why?
|
Follow-Up Studies | 4 | 2015 | 39193 | 0.090 |
Why?
|
Sarcoma | 1 | 2021 | 1802 | 0.090 |
Why?
|
Leukocytes | 1 | 2018 | 2027 | 0.090 |
Why?
|
Cholangiocarcinoma | 1 | 2016 | 578 | 0.080 |
Why?
|
Bile Duct Neoplasms | 1 | 2016 | 626 | 0.080 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4850 | 0.080 |
Why?
|
Proportional Hazards Models | 3 | 2024 | 12509 | 0.080 |
Why?
|
Lymph Node Excision | 1 | 2016 | 1259 | 0.080 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2022 | 2329 | 0.080 |
Why?
|
Germ-Line Mutation | 1 | 2018 | 1884 | 0.080 |
Why?
|
Treatment Failure | 1 | 2015 | 2652 | 0.080 |
Why?
|
Analysis of Variance | 1 | 2017 | 6203 | 0.080 |
Why?
|
Fluorouracil | 3 | 2022 | 1648 | 0.080 |
Why?
|
Robotics | 1 | 2016 | 809 | 0.080 |
Why?
|
Exercise | 2 | 2023 | 5937 | 0.080 |
Why?
|
Brain Neoplasms | 2 | 2022 | 9071 | 0.080 |
Why?
|
Mice, Inbred BALB C | 1 | 2017 | 6220 | 0.070 |
Why?
|
ROC Curve | 1 | 2016 | 3620 | 0.070 |
Why?
|
Lymphatic Metastasis | 1 | 2016 | 2887 | 0.070 |
Why?
|
Blood Platelets | 1 | 2018 | 2464 | 0.070 |
Why?
|
Papillomaviridae | 1 | 2013 | 1141 | 0.070 |
Why?
|
Guideline Adherence | 1 | 2018 | 2243 | 0.070 |
Why?
|
Risk Assessment | 3 | 2020 | 24282 | 0.070 |
Why?
|
Databases, Factual | 2 | 2024 | 8067 | 0.070 |
Why?
|
Bone Marrow | 1 | 2017 | 2921 | 0.070 |
Why?
|
DNA, Viral | 1 | 2013 | 2199 | 0.070 |
Why?
|
HIV | 1 | 2013 | 1585 | 0.070 |
Why?
|
Genome, Human | 1 | 2019 | 4448 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10729 | 0.060 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2024 | 3537 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15398 | 0.060 |
Why?
|
Insurance Coverage | 1 | 2016 | 1944 | 0.060 |
Why?
|
Patient Selection | 1 | 2016 | 4255 | 0.060 |
Why?
|
Odds Ratio | 1 | 2016 | 9649 | 0.050 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2016 | 1643 | 0.050 |
Why?
|
Age Factors | 2 | 2018 | 18380 | 0.050 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12056 | 0.050 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2023 | 299 | 0.050 |
Why?
|
Risk Factors | 4 | 2016 | 74840 | 0.050 |
Why?
|
Guanosine Triphosphate | 1 | 2022 | 313 | 0.050 |
Why?
|
Mutation | 3 | 2022 | 30198 | 0.050 |
Why?
|
Yttrium Radioisotopes | 1 | 2022 | 116 | 0.050 |
Why?
|
Incidence | 2 | 2018 | 21480 | 0.050 |
Why?
|
Peritoneal Lavage | 1 | 2021 | 31 | 0.050 |
Why?
|
Healthcare Disparities | 1 | 2016 | 3413 | 0.040 |
Why?
|
Disease Progression | 1 | 2017 | 13632 | 0.040 |
Why?
|
Hypoalbuminemia | 1 | 2020 | 90 | 0.040 |
Why?
|
Peritoneum | 1 | 2021 | 224 | 0.040 |
Why?
|
Cohort Studies | 2 | 2024 | 41649 | 0.040 |
Why?
|
Quinazolines | 2 | 2017 | 1364 | 0.040 |
Why?
|
Microspheres | 1 | 2022 | 773 | 0.040 |
Why?
|
Philadelphia | 1 | 2019 | 267 | 0.040 |
Why?
|
Lung | 1 | 2017 | 10033 | 0.040 |
Why?
|
Marital Status | 1 | 2019 | 426 | 0.040 |
Why?
|
Germ Cells | 1 | 2022 | 647 | 0.040 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 904 | 0.040 |
Why?
|
Protein Isoforms | 1 | 2022 | 1718 | 0.040 |
Why?
|
Registries | 2 | 2016 | 8297 | 0.030 |
Why?
|
Pennsylvania | 1 | 2018 | 614 | 0.030 |
Why?
|
Cytodiagnosis | 1 | 2021 | 453 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2013 | 1776 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2013 | 22223 | 0.030 |
Why?
|
Particle Accelerators | 1 | 2016 | 174 | 0.030 |
Why?
|
Esophagogastric Junction | 1 | 2017 | 351 | 0.030 |
Why?
|
Four-Dimensional Computed Tomography | 1 | 2016 | 140 | 0.030 |
Why?
|
Protein Conformation | 1 | 2022 | 3946 | 0.030 |
Why?
|
Carboplatin | 1 | 2017 | 789 | 0.030 |
Why?
|
Malnutrition | 1 | 2020 | 629 | 0.030 |
Why?
|
Skin | 1 | 2008 | 4489 | 0.030 |
Why?
|
Consensus | 1 | 2023 | 3202 | 0.030 |
Why?
|
Prospective Studies | 3 | 2023 | 54802 | 0.030 |
Why?
|
Breast Neoplasms | 2 | 2018 | 21056 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2022 | 2878 | 0.030 |
Why?
|
DNA Repair | 1 | 2022 | 2048 | 0.030 |
Why?
|
Maximum Tolerated Dose | 1 | 2014 | 898 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 2015 | 1886 | 0.020 |
Why?
|
Endosonography | 1 | 2016 | 626 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 2 | 2021 | 36532 | 0.020 |
Why?
|
Mastectomy, Segmental | 1 | 2016 | 964 | 0.020 |
Why?
|
Medically Uninsured | 1 | 2016 | 838 | 0.020 |
Why?
|
Lymphocytes | 1 | 2018 | 2599 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2014 | 1589 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2021 | 5302 | 0.020 |
Why?
|
Weight Loss | 1 | 2020 | 2710 | 0.020 |
Why?
|
Monocytes | 1 | 2018 | 2595 | 0.020 |
Why?
|
Piperidines | 1 | 2017 | 1664 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2018 | 4893 | 0.020 |
Why?
|
Skin Care | 1 | 2008 | 54 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2015 | 6069 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2023 | 10383 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2022 | 5696 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2017 | 2822 | 0.020 |
Why?
|
Pain | 1 | 2021 | 5077 | 0.020 |
Why?
|
Neutrophils | 1 | 2018 | 3776 | 0.020 |
Why?
|
Young Adult | 3 | 2018 | 59889 | 0.020 |
Why?
|
Animals | 1 | 2017 | 168764 | 0.010 |
Why?
|
Preoperative Care | 1 | 2013 | 2267 | 0.010 |
Why?
|
Insurance, Health | 1 | 2016 | 2521 | 0.010 |
Why?
|
Palliative Care | 1 | 2018 | 3645 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2015 | 3655 | 0.010 |
Why?
|
Medicaid | 1 | 2016 | 2833 | 0.010 |
Why?
|
Quality of Life | 1 | 2024 | 13462 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2015 | 11022 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 2016 | 3529 | 0.010 |
Why?
|
Ultrasonography | 1 | 2014 | 5993 | 0.010 |
Why?
|
Population Surveillance | 1 | 2008 | 2590 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2021 | 20659 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2018 | 11083 | 0.010 |
Why?
|
Adolescent | 2 | 2016 | 88835 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 2008 | 5849 | 0.000 |
Why?
|
Concepts
(223)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(3)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_